A biodegradable polymeric carrier based on PEG for drug delivery

Journal of Bioactive and Compatible Polymers

Volumn 24, Issue 3, 2009, Pages 220-234

  Mero, Anna ^a   Schiavon, Oddone ^a   Pasut, Gianfranco ^a   Veronese, Francesco M ^a   Emilitri, Elisa ^b   Ferruti, Paolo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anticancer drug; Biodegradable polymeric carrier; Cell internalization; Controlled delivery of camptothecin derivative (SN38); EPR effect; Poly(ethylene) glycol; Prodrugs; Taxol and epirubicin.

Indexed keywords

ANTICANCER-DRUG; BIODEGRADABLE POLYMERIC CARRIER; CELL INTERNALIZATION; CONTROLLED DELIVERY OF CAMPTOTHECIN DERIVATIVE (SN38); EPR EFFECT; PRODRUGS; TAXOL AND EPIRUBICIN.;

BIODEGRADABLE POLYMERS; BIODEGRADATION; BODY FLUIDS; CONTROLLED DRUG DELIVERY; COPOLYMERIZATION; ELECTRON RESONANCE; ELECTRON SPIN RESONANCE SPECTROSCOPY; ESTERS; ETHYLENE; ETHYLENE GLYCOL; ORGANIC POLYMERS; PARAMAGNETIC RESONANCE; POLYETHYLENE OXIDES; QUANTUM THEORY; THERMOGRAVIMETRIC ANALYSIS;

POLYETHYLENE GLYCOLS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYL GROUP; COPOLYMER; DRUG CARRIER; EPIRUBICIN; ESTER; FUMARIC ACID; GLYCOLIC ACID DERIVATIVE; HYDRAZONE DERIVATIVE; MACROGOL 4000; PACLITAXEL;

ACIDITY; ARTICLE; BIODEGRADABILITY; CELLULAR DISTRIBUTION; CHEMICAL BOND; CHEMICAL REACTION; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ENDOSOME; IN VITRO STUDY; KIDNEY CLEARANCE; LYSOSOME; MOLECULAR WEIGHT; PLASMA;

EID: 65649150334     PISSN: 08839115     EISSN: 15308030     Source Type: Journal    
DOI: 10.1177/0883911509103783     Document Type: Article

References (19)

1. Pasut, G., Guiotto, A. and Veronese, F.M. (2004). Protein, Peptide and Non-peptide Drug PEGylation for Therapeutic Application, Exp. Opin. Ther. Pat., 14 (6). 859-894. (Pubitemid 38868068)
2. Singer, J.W. (2005). Paclitaxel Poliglumex (XYOTAX, CT-2103): a Macromolecular Taxane, J. Contr. Rel., 109 (1). 120-126. (Pubitemid 41737258)
3. Chipman, S.D., Oldham, F.B., Pezzoni, G. and Singer, J.W. (2006). Biological and Clinical Characterization of Paclitaxel Poliglumex (PPX, CT-2103), a Macromolecular Polymer-Drug Conjugate, Int. J. Nanomedicine, 1 (4). 375-383.
4. Greco, F. and Vicent, M.J. (2008). Polymer-Drug Conjugates: Current Status and Future Trends, Front. Biosci., 13 (7). 2744-2756.
5. Duncan, R. (2006). Polymer Conjugates as Anticancer Nanomedicines, Nat. Rev. Cancer, 6: 688-701. (Pubitemid 44286001)
6. Torchilin, V. (2000). Drug Targeting, Eur. J. Pharm. Sci., 11 (2). 81-91.
7. Pasut, G. and Veronese, F.M. (2007). Polymer-drug Conjugation, Recent Achievements and General Strategies, Prog. Polym. Sci., 32 (8-9). 933-961. (Pubitemid 47198290)
8. Yamaoka, T., Tabata, Y. and Ikada, Y. (1994). Distribution and Tissue Uptake of Poly(ethylene glycol) with Different Molecular Weights after Intravenous Administration to Mice, J. Pharm. Sci., 83 (4). 601-606. (Pubitemid 24222392)
9. Greco, F., Vicent, M.J., Gee, S., Jones, A.T., Gee, J., Nicholson, R.I., et al. (2007). Investigating the Mechanism of Enhanced Cytotoxicity of HPMA Copolymer-Dox-AGM in Breast Cancer Cells, J. Contr. Release, 117 (1). 28-39. (Pubitemid 46164864)
10. Maeda, H. (2001). The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: the Key Role of Tumor-selective Macromolecular Drug Targeting, Adv. Enzyme. Regul., 41 (1). 189-207. (Pubitemid 32520323)
11. Leonelli, F., La Bella, A., Migneco, L.M. and Bettolo, R.M. (2008) Design, Synthesis and Applications of Hyaluronic Acid-paclitaxel Bioconjugates, Molecules, 13 (2). 360-378.
12. Guan, H., McGuire, M.J., Li, S. and Brown, K.C. (2008) Peptide-targeted Polyglutamic Acid Doxorubicin Conjugates for the Treatment of alpha(v)-beta(6)-Positive Cancers, Bioconj. Chem., 19 (9). 1813-1821.
13. Zhao, H., Rubio, B., Sapra, P., Wu, D., Reddy, P., Sai, P. et al. (2008) Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers, Bioconjug. Chem., 19 (4). 849-859.
14. Greenwald, R.B. (2001). PEG Drugs: An Overview, J. Contr. Release, 74 (1). 159-171. (Pubitemid 32727618)
15. Ulbrich, K., Etrych, T., Chytil, P., Pechar, M., Jelinkova, M. and Rihova, B. (2004). Polymeric Anticancer Drugs with pH-Controlled Activation, Int. J. Pharm., 277 (1-2). 63-72. (Pubitemid 38670421)
16. Ulbrich, K. and Subr, V. (2004). Polymeric Anticancer Drugs with pH-Controlled Activation, Adv. Drug Del. Rev., 56 (7). 1023-1050. (Pubitemid 38520207)
17. Snyder, S.M.L. and Sobocinski, P.Z. (1975). An Improved 2,4,6-Trinitrobenzenesulfonic Acid Method for the Determination of Amines, Analytical Biochem., 64 (1). 284-288.
18. Andersson, L., Davies, J., Duncan, R., Ferruti, P., Ford, J., Kneller, S. et al. (2005). Poly(ethylene glycol)-Poly(ester-carbonate) Block Copolymers Carrying PEG-Peptidyl-Doxorubicin Pendant Side Chains: Synthesis and Evaluation as Anticancer Conjugates, Biomacromolecules, 6 (2). 914-926. (Pubitemid 40467837)
19. Greenwald, R.B., Gilbert, C.W., Pendri, A., Conover, C.D., Xia, J. and Martinez, A. (1996). Drug Delivery Systems: Water Soluble Taxol 20-Poly(ethylene glycol) Ester Prodrugs-Design and in Vivo Effectiveness, J. Med. Chem., 39 (2). 424-431. (Pubitemid 26037894)